Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. - Test2 - elhamkhani - TriplyDB

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

http://www.wikidata.org/entity/Q36934286

about

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Targeting caspases in cancer therapeutics Progress of molecular targeted therapies for prostate cancers Systems biology of cisplatin resistance: past, present and future Targeting survivin in cancer Targeting the apoptosis pathway in hematologic malignancies Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.Cell death The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy.Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.Survivin is not induced by novel taxanes.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Optimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA.pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members.YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo.Novel therapeutics for aggressive non-Hodgkin's lymphoma.Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.Report of the EORTC-PAMM Meeting, Brussels, 16-18 March 2009: new strategies for a targeted and personalised therapy of cancer.A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy.Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

P2860

Q26771601-CBD2E511-A8EC-4F0C-B206-7EC3EA219F96 Q26821986-2C888146-18C8-4C61-A696-962D94096387 Q26823014-A855B2C1-A6B2-4141-B21F-46CD0846D755 Q26863585-3DB1C222-8D2E-4573-A68E-8BBF5C58AB7A Q27012954-D22B6789-DC6D-42BA-B96A-6D01E93EC893 Q27024422-C2969CD1-CCFC-450A-853D-8B3D42DC1641 Q28386284-44CD1039-625C-45B4-8099-96F8B6465849 Q28483886-8D7E23C8-7778-469E-AB07-E2536625B99C Q28485864-5D762D3D-264A-4435-ABF8-4FCF71E5EB5A Q33429865-9F5C959A-0D85-4720-8EA9-2ED323EEA28C Q33499385-CC02F319-467C-4513-A894-A75E6C46E8F2 Q33634679-6C48CDD2-810A-47F5-A1BB-E0900C831E2B Q33827053-C2CA3495-4E53-45C0-B251-45672D53943D Q33926307-41FF89E8-1D60-4954-9F39-46BB3C18B20D Q33988315-0870C121-1F19-430B-86EA-33C7D846A63E Q34019760-E742FC37-1982-4628-8ECD-A964D788FC5F Q34059707-DC5BAB55-A06D-4FDB-A1AF-9ED6E54FAB13 Q34220632-545AF795-CBA4-48C8-9382-5953AB8DC2C1 Q34234351-D1DABB51-3F1B-4C73-B0C9-E9E9D4C294C9 Q34334471-1B4F7E55-905F-41DB-860B-2BC8F55E41F0 Q34415628-9F85DA16-C382-4271-86D7-439615B2D086 Q34515007-B7CA6BA8-F6D8-4486-BF13-D7DB8F516011 Q34559630-6033224E-5DFD-4BF5-88E6-EE91A6372536 Q34630304-F678758C-509C-44E4-8C0A-BA1195A424F4 Q34795766-EA15C0E9-FD10-4D4C-82BB-BE6358CB5C19 Q34871780-FF9A95DA-D5C2-47BF-8C65-A6D1157157A8 Q34983601-C9B5F4D6-2ECC-4AE1-9CE3-71CB1BD9A6C1 Q34992551-4C3B92B1-E00B-406A-ACB5-5A4ECC332E81 Q35111768-CA50A346-AA5A-464D-AA02-5147575EAB9B Q35294613-E18AC024-E7EC-4C95-A3C9-04B83146CF8C Q35572921-6202E432-A9F3-4C13-89E2-601FBB3E430C Q35602111-83F27630-1679-418D-8899-10E7F2CE74C4 Q35981061-7A6DD9FD-6E77-4C61-9008-249E0FFCA6FA Q36070338-0044E2F3-D116-4E23-8EBF-EF539CD82AD7 Q36073279-13B9C14F-F6E1-4D0C-9C58-726FB4E098D1 Q36121849-86624AD8-5C42-4E26-9EEF-54B6EBD80D5D Q36192077-176ACCBC-7192-4E89-95FD-90F2CA69697E Q36198307-E879D9EE-3A11-4753-AB3F-D43D1130B73C Q36660459-CE7FD683-CBE1-4BEA-80B8-E0EEE68DE525 Q36682843-1037B2B9-8F82-424D-8420-4F73D756579D

P2860

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

http://www.wikidata.org/entity/Q36934286

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

@en

type

label

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

@en

prefLabel

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

@en

P1433

Q36934286-A661D70C-D02E-4800-B50D-A195E652FE53

P1476

Q36934286-FC44EE51-13FB-4896-A68D-F315149CCDFC

P2093

Q36934286-14606CCA-A9D8-44E9-8E4A-E7680F8961C1

Q36934286-2F5125D4-1247-41DF-ACD7-FE961BA1EE69

Q36934286-67AB007E-3579-40A6-BD4D-30A0F6DFA609

Q36934286-6FC967D6-4487-450F-9F42-DFE32A02B90A

Q36934286-80CF202A-28C6-44DB-8FA0-852CF009BD64

Q36934286-96DAEB58-F389-4B09-AA51-28A55C53AAF2

Q36934286-AB056AB1-98F9-47C6-80FB-44AB30447E02

Q36934286-C3E527FE-5FCC-43E1-9783-3AB374FF24A0

Q36934286-CFBCE9EF-79E9-44CA-9AE0-5C65D686C96F

Q36934286-D723D9BB-0087-476B-A7D7-28EC16C4C96B

P2860

Q36934286-0441104F-67E5-412B-BED2-65E4AB05F58F

Q36934286-046FA516-5E20-4181-ABC2-2CD144D5CF9E

Q36934286-17A8D110-B74A-41BC-85B5-F6289CAF29A3

Q36934286-1BF6C027-E962-4B9F-A054-66B98138E5BF

Q36934286-2A65EF19-5129-4932-8FDC-0004CAD26CA7

Q36934286-2D6113B1-EB7E-4F17-9738-F548FEC8ECBA

Q36934286-5CD18559-B28A-47E8-87F1-5AA7FBCA793D

Q36934286-62F833F1-CFE9-457A-A3A8-4A6AAD43B65E

Q36934286-8145208C-B458-426D-AAC0-2F93FA15B70B

Q36934286-9F54C605-946A-49C7-9D5D-2A3D04EF5DA2

P304

Q36934286-ED76A811-0475-4558-9FCD-08F36E665BE1

P31

Q36934286-C5FA69FC-FE2A-41A5-B8DB-09DF50C13C23

P356

Q36934286-781E8206-EA9D-41B3-883E-DF0C0A49DBD5

P407

Q36934286-822E48C5-EFDA-4F2B-A2A2-4B602139ADA1

P433

Q36934286-9D4213D9-A63B-4E90-9B7C-67111CBED8EF

P478

Q36934286-F0DFD977-EC74-46B1-9E95-1CB03B4DDFA0

P50

Q36934286-0BCC04A0-DD67-44E0-B0CD-ADEB65DD0B3A

P577

Q36934286-479E406F-94EF-467E-A3C9-6DD898E01D4B

P698

Q36934286-02262E52-728F-4140-AEF9-5E7244205EBD

P932

Q36934286-7DE12A1A-98D9-475C-B60B-B91B3D65B4B9

P356

JCO.2008.17.2064

P1433

Journal of Clinical Oncology

P1476

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin

@en

P2093

Alain Mita

http://www.w3.org/2001/XMLSchema#string

Amita Patnaik

http://www.w3.org/2001/XMLSchema#string

Anne Keating

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Chris Takimoto

http://www.w3.org/2001/XMLSchema#string

Christopher R Garrett

http://www.w3.org/2001/XMLSchema#string

Elizabeth Till

http://www.w3.org/2001/XMLSchema#string

Kyri Papadopoulos

http://www.w3.org/2001/XMLSchema#string

Lionel D Lewis

http://www.w3.org/2001/XMLSchema#string

Pamela Bartels

http://www.w3.org/2001/XMLSchema#string

P2860

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

Solution structure of human survivin and its binding interface with Smac/Diablo

Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin

The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm.

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.

An IAP-IAP complex inhibits apoptosis.

Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma.

Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

P304

5198-5203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.17.2064

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18824702

http://www.w3.org/2001/XMLSchema#string

P932

4879696

http://www.w3.org/2001/XMLSchema#string